~~<i id='EA7E8C87F2'><strike id='EA7E8C87F2'><tt id='EA7E8C87F2'><pre id='EA7E8C87F2'></pre></tt></strike></i>~~

Home» comprehensive» Wikipedia

Wikipedia

author：explore 2025-09-30 02:03:07 Page View：27715

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The public health thinking behind the CDC’s new Covid guidance
Next article： New air purifier tech could be key to improving indoor air quality

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Use doctors trained outside the U.S. to ease the physician shortage

AdobeThislegislativesession,Gov.BillLeemadehistorybysigningabillthatmakesTennesseethefirststateinthe

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Fatty liver disease was alleviated by Lilly’s ‘triple

Largevacuolesoftriglyceridefat,accumulatedinsidelivercells.AdobeSANDIEGO—Anexperimentalobesitydrugfr